Neurocrine Biosciences, Inc. (NBIX) compared with its closest peers (AMGN, ABT, GILD, PFE, VRTX): P/E 22.0 vs industry 17.2. Peer set by Business model: Big Pharma / Branded Drugs; 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Amgen Inc. (AMGN) | $234.11B | 30.0 |
| Abbott Laboratories (ABT) | $198.97B | 31.7 |
| Gilead Sciences, Inc. (GILD) | $178.07B | 19.3 |
| Pfizer Inc. (PFE) | $158.34B | 36.5 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $137.09B | 31.1 |
| Bristol-Myers Squibb Company (BMY) | $133.80B | 14.4 |
| Regeneron Pharmaceuticals, Inc. (REGN) | $87.65B | 20.8 |
| Moderna, Inc. (MRNA) | $51.98B | -4.1 |
| Biogen Inc. (BIIB) | $31.69B | 23.1 |
| Zoetis Inc. (ZTS) | $31.47B | 11.9 |
| Stock P/E | 22.0 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 2.0% |
| vs Industry | 28.3% |
NBIX overview · NBIX earnings · NBIX financials · NBIX KPIs · NBIX investor relations · NBIX ownership · NBIX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.